Teva will be forced to pay the Nevada patient the full $500 million in damages because the company was deemed responsible for the hepatitis C outbreak from tainted Propofol vials.
An arbitration panel in Delaware ruled that Teva was bound by an agreement with Baxter to cover the liability after the company sold its rights to use Propofol until 2009, according to the report. Teva is currently facing almost 300 lawsuits from patients infected with hepatitis C in Nevada alone.
Related Articles on Anesthesia:
Couple Testifies Against Teva and Baxter in Second Trial Over Hep C Outbreak
Play About Discovery of Anesthesia Premieres in Houston
Kaweah Delta Health Care District President Explains Rationale Behind Anesthesia Provider Switch
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.